(Q39567948)

13 September 2017

title

Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells (English)

1 reference

13 September 2017

main subject

myelodysplastic syndrome

1 reference

Jian Huang

1

1 reference

13 September 2017

Ting Ding

2

1 reference

13 September 2017

Min Yang

3

1 reference

13 September 2017

Hui Liu

4

1 reference

13 September 2017

Xin Sun

5

1 reference

13 September 2017

Jie Jin

6

1 reference

13 September 2017

publication date

31 March 2011

1 reference

International Journal of Hematology

13 September 2017

published in

1 reference

13 September 2017

volume

93

1 reference

13 September 2017

issue

4

1 reference

13 September 2017

page(s)

482-493

1 reference

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

The role of proteasome inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

The development and pharmacology of proteasome inhibitors for the management and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Proteasome inhibitors: a therapeutic strategy for haematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Proteasome inhibitors in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

The proteasome as a potential target for novel anticancer drugs and chemosensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Bcl-2 changes conformation to inhibit Bax oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Activators and target genes of Rel/NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Myelodysplastic Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0821-Z

Nuclear factor k B is activated in myelodysplastic bone marrow cells

21 January 2018

1 reference

12 December 2020

Akt associates with nuclear factor kappaB and plays an important role in chemoresistance of gastric cancer cells

1 reference

12 December 2020

Myelodysplastic syndromes

1 reference

12 December 2020

Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90

1 reference

12 December 2020

Proteasome system of protein degradation and processing

1 reference

12 December 2020

Novel therapies for relapsed myeloma

1 reference

12 December 2020

Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma

1 reference

12 December 2020

Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy.

1 reference

12 December 2020

10.1007/S12185-011-0821-Z

Identifiers

DOI

1 reference

release_t3apkqiqc5hibcqtpqenstolku

13 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/t3apkqiqc5hibcqtpqenstolku

24 November 2022

mapped directly with Wikidata item

1 reference